Life after death: targeting high mobility group box 1 in emergent cancer therapies.
Explore this paper's citation graph
Summary
It is hypothesized that HMGB1 also functions as an epigenetic modifier, mainly through regulation of NF-kB-dependent signaling pathways, to modulate the behavior of surviving cancer cells as well as the immune cells found within the tumor microenvironment, which has significant implications for developing novel cancer therapeutics.
- Type
- article
- Published
- 2013-01-01
- Cited by
- 81
- References
- 157
- OpenAlex
- https://openalex.org/W177603265
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:24257766
Keywords
HMGB1, Cancer cell, Immune system, Tumor microenvironment, Cancer
References
- Epigenetic control in the immune response.
- Keeping up NF-kappaB appearances: epigenetic control of immunity or inflammation-triggered epigenetics.
- Autophagy regulation in cancer development and therapy.
- Apicidin and docetaxel combination treatment drives CTCFL expression and HMGB1 release acting as potential antitumor immune response inducers in metastatic breast cancer cells.
- DNA Alkylating Therapy Induces Tumor Regression through an HMGB1-Mediated Activation of Innate Immunity
- Innate immunity to mycobacteria: vitamin D and autophagy
- Oxidation of the alarmin high-mobility group box 1 protein (HMGB1) during apoptosis
- High Mobility Group B1 Protein Suppresses the Human Plasmacytoid Dendritic Cell Response to TLR9 Agonists1
- Structural Basis for the Proinflammatory Cytokine Activity of High Mobility Group Box 1
- The role of IFN-alpha and nitric oxide in the release of HMGB1 by RAW 264.7 cells stimulated with polyinosinic-polycytidylic acid or lipopolysaccharide.
- Inhibitor of NF-κB Kinases α and β Are Both Essential for High Mobility Group Box 1-Mediated Chemotaxis
- Redox Modification of Cysteine Residues Regulates the Cytokine Activity of High Mobility Group Box-1 (HMGB1)
- The DNA-bending protein HMG-1 enhances progesterone receptor binding to its target DNA sequences
- Effect of HMGB1 silencing on cell proliferation, invasion and apoptosis of MGC‐803 gastric cancer cells
- Knockdown of High Mobility Group Box 1 in Tumor Cells Attenuates Their Ability to Induce Regulatory T Cells and Uncovers Naturally Acquired CD8 T Cell-dependent Antitumor Immunity
- Nucleocytoplasmic Shuttling of HMGB1 Is Regulated by Phosphorylation That Redirects It toward Secretion1
- Structure of the HMG box motif in the B‐domain of HMG1.
- Preserving Sialic Acid-dependent Pattern Recognition by CD24-Siglec G Interaction for Therapy of Polybacterial Sepsis
- The human HMGB1 promoter is modulated by a silencer and an enhancer-containing intron.
- Danger signaling protein HMGB1 induces a distinct form of cell death accompanied by formation of giant mitochondria.
Cited by
- Down-regulation of HMGB1 expression by shRNA constructs inhibits the bioactivity of urothelial carcinoma cell lines via the NF-κB pathway
- Combining oncolytic immunotherapy with conventional cancer treatments
- Prognostic value of the high-mobility group box-1 in young patients with chest pain
- Oncolytic Immunotherapy: Dying the Right Way is a Key to Eliciting Potent Antitumor Immunity
- Biomarkers of liver cell death.
- Suppression of toll-like receptor 2 expression inhibits the bioactivity of human hepatocellular carcinoma
- Inhibiting Autophagy: A Novel Approach for the Treatment of Renal Cell Carcinoma
- Ultraviolet-radiation-induced inflammation promotes angiotropism and metastasis in melanoma
- HMGB1 in Hormone-Related Cancer: a Potential Therapeutic Target
- Immunogenic HSV-mediated oncolysis shapes the antitumor immune response and contributes to therapeutic efficacy.
- HMGB1 Promotes a p38MAPK Associated Non-Infectious Inflammatory Response Pathway in Human Fetal Membranes
- Upregulation of heat shock proteins and the promotion of damage-associated molecular pattern signals in a colorectal cancer model by modulated electrohyperthermia
- Serum HMGB1 is a predictive and prognostic biomarker for oncolytic immunotherapy
- Extracellular HMGB1 promotes differentiation of nurse-like cells in chronic lymphocytic leukemia.
- Changing Faces in Virology: The Dutch Shift from Oncogenic to Oncolytic Viruses
- Complementary Induction of Immunogenic Cell Death by Oncolytic Parvovirus H-1PV and Gemcitabine in Pancreatic Cancer
- MRTF‐A and STAT3 promote MDA‐MB‐231 cell migration via hypermethylating BRSM1
- Association of Upregulated HMGB1 and c-IAP2 Proteins With Hepatocellular Carcinoma Development and Progression
- Radio-Immunotherapy-Induced Immunogenic Cancer Cells as Basis for Induction of Systemic Anti-Tumor Immune Responses – Pre-Clinical Evidence and Ongoing Clinical Applications
- IL-1β, RAGE and FABP4: targeting the dynamic trio in metabolic inflammation and related pathologies
Related papers
- A Toll-like receptor recognizes bacterial DNA
- Removal of T cells from bone marrow for transplantation: a monoclonal antilymphocyte antibody that fixes human complement.
- Mutations in the conserved loop of human U5 snRNA generate use of novel cryptic 5′ splice sites in vivo.
- Induction of Neutralization Antibodies in Mice by Dengue-2 Envelope DNA Vaccines
- B lymphocyte stimulator: a new target for treating B cell malignancies.
- Assembly and traffic of small nuclear RNPs.
- Nanoparticulate systems for polynucleotide delivery